CYP2C19 Metabolizer Status and Clopidogrel Efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) Study [Genetics]
Conclusions
There were significant differences in recurrent stroke by CYP2C19 genotype-inferred metabolizer status in white subcortical stroke patients receiving dual antiplatelet therapy with aspirin and clopidogrel, consistent with cardiovascular studies on CYP2C19 and clopidogrel; however, the bleeding risk that led to early termination of the antiplatelet arm of the SPS3 trial does not appear to be explained by CYP2C19 genotype. This study was relatively underpowered; therefore, these findings should be interpreted with caution and warrant replication.
Clinical Trial Registration
URL: www.clinicaltrials.gov. Unique identifier: NCT00059306.
Source: JAHA:Journal of the American Heart Association - Category: Cardiology Authors: McDonough, C. W., McClure, L. A., Mitchell, B. D., Gong, Y., Horenstein, R. B., Lewis, J. P., Field, T. S., Talbert, R. L., Benavente, O. R., Johnson, J. A., Shuldiner, A. R. Tags: Genetics Source Type: research
More News: Angioplasty | Aspirin | Bleeding | Cardiology | Cardiovascular | Clinical Trials | Clopidogrel | Coronary Angioplasty | Genetics | Heart | Percutaneous Coronary Intervention | Plavix | Stroke | Study